Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study

Publication | Open Access

DOI Full Paper Access

121

Citations

References

2017

Year

Josef S Smolen, Jung‐Yoon Choe, Nenad Prodanović, Jaroslaw Niebrzydowski, Ivan Staykov, Eva Dokoupilová, Asta Baranauskaitė, Roman Yatsyshyn, Mevludin Mekić, W. Porawska,

Annals of the Rheumatic Diseases